Cover Image
市場調查報告書

缺鐵性貧血:開發平台分析

Iron Deficiency Anemia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213042
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
缺鐵性貧血:開發平台分析 Iron Deficiency Anemia - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 76 Pages
簡介

所謂貧血可說是體內紅血球不足的狀態。鐵分有助於生產紅血球,但體內鐵分一旦不足,所生產的紅血球便會減少,或是尺寸過小,這就叫做缺鐵性貧血。症狀有焦躁感和頭痛,集中力和思考力問題等,治療方法有大量攝取補充品和含鐵分的食品等。

本報告涵括全球缺鐵性貧血治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及他們開發中的產品評估等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

缺鐵性貧血概要

治療藥的開發

  • 缺鐵性貧血開發中產品:概要
  • 缺鐵性貧血開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Panion & Bf Biotech Inc
  • Rockwell Medical, Inc.
  • Vifor Pharma AG

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ferric carboxymaltose
  • ferric citrate
  • ferric maltol
  • ferric pyrophosphate citrate
  • NSC-8679
  • Proteins to Activate Erythroferrone for Iron Deficiency Anemia
  • VIT-91

最新開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8979IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H1 2017, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 3, 1, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Iron Deficiency Anemia - Overview
  • Iron Deficiency Anemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Iron Deficiency Anemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Iron Deficiency Anemia - Companies Involved in Therapeutics Development
    • Galenica Ltd
    • Johnson & Johnson
    • Novartis AG
    • Panion & Bf Biotech Inc
    • Pieris Pharmaceuticals Inc
    • Rockwell Medical Inc
    • Shield Therapeutics Plc
  • Iron Deficiency Anemia - Drug Profiles
    • CSJ-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric carboxymaltose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric maltol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric pyrophosphate citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-42905343 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSC-8679 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRS-080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PT-30 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Iron Deficiency Anemia - Dormant Projects
  • Iron Deficiency Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Jan 12, 2017: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology
      • Jan 08, 2017: Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference
      • Jan 06, 2017: Shield Therapeutics Provides Business Update
      • Dec 07, 2016: EFFECT-HF demonstrates a significantly beneficial effect of Ferinject on exercise capacity among patients with chronic heart failure and iron deficiency - confirms findings of previous studies
      • Nov 17, 2016: Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
      • Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
      • Sep 07, 2016: Shield Therapeutics Announces Composition of Matter Patent Granted on Feraccru
      • Jun 17, 2016: Feraccru (ferric maltol) launched in the UK for the treatment of adults with iron deficiency anemia in patients with inflammatory bowel disease
      • Apr 28, 2016: Rockwell Medical Announces Triferic Presentation "Overcoming Functional Iron Deficiency in Your Hemodialysis Patients" at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston
      • Mar 29, 2016: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease
      • Mar 21, 2016: China FDA Accepts Rockwell Medical's Triferic Drug Submission for Commercialization in China
      • Feb 26, 2016: Feraccru receives marketing authorisation in Europe
      • Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia
      • Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA
      • Dec 18, 2015: Shield Therapeutics announces receipt of a positive opinion from the CHMP recommending the approval of Feraccru for the treatment of iron deficiency anemia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Iron Deficiency Anemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Iron Deficiency Anemia - Pipeline by Galenica Ltd, H1 2017
  • Iron Deficiency Anemia - Pipeline by Johnson & Johnson, H1 2017
  • Iron Deficiency Anemia - Pipeline by Novartis AG, H1 2017
  • Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H1 2017
  • Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals Inc, H1 2017
  • Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, H1 2017
  • Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H1 2017
  • Iron Deficiency Anemia - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Iron Deficiency Anemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top